Insider trade

Officer sold ~$550K of UTHR shares in the open market

Traded Jul 2, 2026 · Filed Jul 3, 2026

Why it stands out

United Therapeutics's & GENERAL COUNSEL sold $550K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$550,267

Shares × reported transaction price

Timing vs results

57 days after results of May 6, 2026, 34 days before results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−2.1%	−0.3%	−1.9%
30 days	−5.2%	+2.5%	−7.6%
90 days	−2.0%	+3.1%	−5.1%

Past results only. Not a forecast.

This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
This transaction was executed in multiple trades at prices ranging from $555.16 to $556.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 2mo ago

Traded Jul 30 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 2mo ago

Scheduled in advanceFiled 2mo ago